Innovent Enters into Clinical Trial Collaboration with RemeGen
Monday, June 26, 2023
Innovent and RemeGen have entered into a clinical trial collaboration to investigate a combination therapy involving TYVYT® (sintilimab injection), an immune checkpoint inhibitor, and novel antibody-drug conjugate (ADC) candidates.
The collaboration between Innovent Biologics and RemeGen introduces an innovative treatment approach by combining RC88 and RC108 with sintilimab.
As part of their agreement, Innovent Biologics will be responsible for supplying TYVYT® (sintilimab injection) as the clinical drug for the collaboration. On the other hand, RemeGen will take the lead in conducting Phase 1/2a clinical studies to assess the safety and anti-tumour activity of combining TYVYT® with either RC88 or RC108. These clinical trials will specifically focus on Chinese patients diagnosed with advanced solid tumours.
This collaboration will focus to explore the potential of combination therapies involving TYVYT® (sintilimab injection) in conjunction with two promising antibody-drug conjugates (ADCs): RC88, which targets mesothelin (MSLN), and RC108, which targets c-Met. These novel ADCs have shown promise in targeting advanced solid tumours.
TYVYT® (sintilimab injection) is a groundbreaking PD-1 inhibitor renowned for its innovative approach to cancer treatment. It has garnered approval for an impressive seven indications in China and has been included in the esteemed National Reimbursement Drug List (NRDL) for six of these indications.
Notably, TYVYT® (sintilimab injection) stands out as the sole PD-1 inhibitor recommended for first-line treatment in five high-incidence cancer types listed in the NRDL. These cancer types include non-squamous NSCLC, squamous NSCLC, hepatocellular carcinoma, esophageal squamous cell carcinoma, and gastric cancer.
